Trial Profile

Pegetron® Redipen™ Prospective Optimal Weight-based Dosing Response Program

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2b/ribavirin (Primary) ; Ribavirin (Primary)
Indications Hepatitis C
Focus Therapeutic Use
Acronyms RediPEN
Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough

Most Recent Events

06 Feb 2016 Results (post hoc pooled analysis of PoWer and RediPEN studies) published in the European Journal of Clinical Microbiology and Infectious Diseases (n = 1242).
31 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
27 Jun 2012 Planned number of patients changed from 1285 to 2320 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com